The article reported on Phase 2 clinical trial data for the use of the monoclonal antibody Lu AG09222ALD-1910 targeting pituitary adenylate cyclase-activating polypeptide (PACAP) in the treatment of migraine.
The global HIV drug market is highly competitive, with multiple pharmaceutical companies collaborating in research and commercialization to provide more effective treatment options.
Relay Therapeutics has announced encouraging interim results for RLY-2608, the initial investigational allosteric, pan-mutant, and isoform-selective inhibitor of PI3Kα.
These findings showcase the efficacy of its innovative EVX-B2 mRNA Gonorrhea vaccine candidate in eradicating gonorrhea bacteria through the induction of a specialized immune response.
ArriVent BioPharma and Allist Pharmaceuticals unveiled groundbreaking data from their global Phase Ib proof-of-concept randomized study (FURTHER) at the IASCLC 2024 WCLC.